[Tinnitus and lipid metabolism disorders. Value of early normolipemic treatment].
D000924:Anticholesteremic Agents / Q000627:therapeutic use; D001791:Blood Platelet Disorders / Q000150:complications; D002792:Cholestyramine Resin / Q000627:therapeutic use; D002994:Clofibrate / Q000627:therapeutic use; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications; D006949:Hyperlipidemias / Q000150:complications*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D002537:Intracranial Arteriosclerosis / Q000150:complications; D002542:Intracranial Embolism and Thrombosis / Q000150:complications; D009539:Nicotinic Acids / Q000627:therapeutic use; D014012:Tinnitus / Q000188:drug therapy / Q000209:etiology*
D000924:Anticholesteremic Agents; D000960:Hypolipidemic Agents; D009539:Nicotinic Acids; D002792:Cholestyramine Resin; D002994:Clofibrate
Bourdonnements d'oreille et troubles métaboliques des lipides. . Intérêt d'un traitement normolipémiant précoce.